Cellectis wins FDA RMAT status for leukemia CAR-T candidate lasme-cel; shares rise



Cellectis wins FDA RMAT status for leukemia CAR-T candidate lasme-cel; shares rise



Source link

You may be interested

Leave a Reply

Your email address will not be published. Required fields are marked *